198 related articles for article (PubMed ID: 30219945)
1. Late toxicity of image-guided hypofractionated radiotherapy for prostate: non-randomized comparison with conventional fractionation.
Jereczek-Fossa BA; Surgo A; Maisonneuve P; Maucieri A; Gerardi MA; Zerini D; Marvaso G; Ciardo D; Volpe S; Rojas DP; Riva G; Alessandro O; Dicuonzo S; Fanetti G; Romanelli P; Starzyńska A; Cattani F; Cambria R; Fodor C; Garibaldi C; Romanò C; De Cobelli O; Orecchia R
Radiol Med; 2019 Jan; 124(1):65-78. PubMed ID: 30219945
[TBL] [Abstract][Full Text] [Related]
2. Acute toxicity of image-guided hypofractionated radiotherapy for prostate cancer: nonrandomized comparison with conventional fractionation.
Jereczek-Fossa BA; Zerini D; Fodor C; Santoro L; Cambria R; Garibaldi C; Tagaste B; Vavassori A; Cattani F; Alterio D; Gherardi F; Serafini F; Rocco B; Musi G; De Cobelli O; Orecchia R
Urol Oncol; 2011; 29(5):523-32. PubMed ID: 20005749
[TBL] [Abstract][Full Text] [Related]
3. Hypofractionated versus conventionally fractionated radiotherapy for patients with prostate cancer (HYPRO): late toxicity results from a randomised, non-inferiority, phase 3 trial.
Aluwini S; Pos F; Schimmel E; Krol S; van der Toorn PP; de Jager H; Alemayehu WG; Heemsbergen W; Heijmen B; Incrocci L
Lancet Oncol; 2016 Apr; 17(4):464-474. PubMed ID: 26968359
[TBL] [Abstract][Full Text] [Related]
4. Improved clinical outcomes with high-dose image guided radiotherapy compared with non-IGRT for the treatment of clinically localized prostate cancer.
Zelefsky MJ; Kollmeier M; Cox B; Fidaleo A; Sperling D; Pei X; Carver B; Coleman J; Lovelock M; Hunt M
Int J Radiat Oncol Biol Phys; 2012 Sep; 84(1):125-9. PubMed ID: 22330997
[TBL] [Abstract][Full Text] [Related]
5. Hypofractionated versus conventionally fractionated radiotherapy for patients with prostate cancer (HYPRO): acute toxicity results from a randomised non-inferiority phase 3 trial.
Aluwini S; Pos F; Schimmel E; van Lin E; Krol S; van der Toorn PP; de Jager H; Dirkx M; Alemayehu WG; Heijmen B; Incrocci L
Lancet Oncol; 2015 Mar; 16(3):274-83. PubMed ID: 25656287
[TBL] [Abstract][Full Text] [Related]
6. A randomised assessment of image guided radiotherapy within a phase 3 trial of conventional or hypofractionated high dose intensity modulated radiotherapy for prostate cancer.
Murray J; Griffin C; Gulliford S; Syndikus I; Staffurth J; Panades M; Scrase C; Parker C; Khoo V; Dean J; Mayles H; Mayles P; Thomas S; Naismith O; Baker A; Mossop H; Cruickshank C; Hall E; Dearnaley D;
Radiother Oncol; 2020 Jan; 142():62-71. PubMed ID: 31767473
[TBL] [Abstract][Full Text] [Related]
7. Role of principal component analysis in predicting toxicity in prostate cancer patients treated with hypofractionated intensity-modulated radiation therapy.
Vesprini D; Sia M; Lockwood G; Moseley D; Rosewall T; Bayley A; Bristow R; Chung P; Ménard C; Milosevic M; Warde P; Catton C
Int J Radiat Oncol Biol Phys; 2011 Nov; 81(4):e415-21. PubMed ID: 21477939
[TBL] [Abstract][Full Text] [Related]
8. Moderate Hypofractionated Postprostatectomy Volumetric Modulated Arc Therapy With Daily Image Guidance (VMAT-IGRT): A Mono-institutional Report on Feasibility and Acute Toxicity.
Fersino S; Tebano U; Mazzola R; Giaj-Levra N; Ricchetti F; Di Paola G; Fiorentino A; Sicignano G; Naccarato S; Ruggieri R; Cavalleri S; Alongi F
Clin Genitourin Cancer; 2017 Aug; 15(4):e667-e673. PubMed ID: 28237181
[TBL] [Abstract][Full Text] [Related]
9. A comparison of treatment outcome between fiducial-based and bone-based image guided radiotherapy in prostate cancer patients.
Napieralska A; Majewski W; Kulik R; Głowacki G; Miszczyk L
Radiat Oncol; 2018 Nov; 13(1):235. PubMed ID: 30482212
[TBL] [Abstract][Full Text] [Related]
10. Rectal/urinary toxicity after hypofractionated vs conventional radiotherapy in low/intermediate risk localized prostate cancer: systematic review and meta analysis.
Di Franco R; Borzillo V; Ravo V; Ametrano G; Falivene S; Cammarota F; Rossetti S; Romano FJ; D'Aniello C; Cavaliere C; Iovane G; Piscitelli R; Berretta M; Muto P; Facchini G
Oncotarget; 2017 Mar; 8(10):17383-17395. PubMed ID: 28129649
[TBL] [Abstract][Full Text] [Related]
11. Late outcomes following hypofractionated conformal radiotherapy vs. standard fractionation for localized prostate cancer: a nonrandomized contemporary comparison.
Leborgne F; Fowler J
Int J Radiat Oncol Biol Phys; 2009 Aug; 74(5):1441-6. PubMed ID: 19395194
[TBL] [Abstract][Full Text] [Related]
12. Nomogram to predict rectal toxicity following prostate cancer radiotherapy.
Delobel JB; Gnep K; Ospina JD; Beckendorf V; Chira C; Zhu J; Bossi A; Messai T; Acosta O; Castelli J; de Crevoisier R
PLoS One; 2017; 12(6):e0179845. PubMed ID: 28640871
[TBL] [Abstract][Full Text] [Related]
13. Oligometastases in prostate cancer : Metabolic response in follow-up PSMA-PET-CTs after hypofractionated IGRT.
Baumann R; Koncz M; Luetzen U; Krause F; Dunst J
Strahlenther Onkol; 2018 Apr; 194(4):318-324. PubMed ID: 29181556
[TBL] [Abstract][Full Text] [Related]
14. Acute genitourinary toxicity after high-dose-rate (HDR) brachytherapy combined with hypofractionated external-beam radiation therapy for localized prostate cancer: correlation between the urethral dose in HDR brachytherapy and the severity of acute genitourinary toxicity.
Akimoto T; Ito K; Saitoh J; Noda SE; Harashima K; Sakurai H; Nakayama Y; Yamamoto T; Suzuki K; Nakano T; Niibe H
Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):463-71. PubMed ID: 16168838
[TBL] [Abstract][Full Text] [Related]
15. Three-dimensional ultrasound-based image-guided hypofractionated radiotherapy for intermediate-risk prostate cancer: results of a consecutive case series.
Ricardi U; Franco P; Munoz F; Levis M; Fiandra C; Guarneri A; Moretto F; Bartoncini S; Arcadipane F; Badellino S; Piva C; Trino E; Ruggieri A; Filippi AR; Ragona R
Cancer Invest; 2015 Mar; 33(2):23-8. PubMed ID: 25526035
[TBL] [Abstract][Full Text] [Related]
16. Evidence for efficacy without increased toxicity of hypofractionated radiotherapy for prostate carcinoma: early results of a Phase III randomized trial.
Yeoh EE; Fraser RJ; McGowan RE; Botten RJ; Di Matteo AC; Roos DE; Penniment MG; Borg MF
Int J Radiat Oncol Biol Phys; 2003 Mar; 55(4):943-55. PubMed ID: 12605972
[TBL] [Abstract][Full Text] [Related]
17. Rectal/urinary toxicity after hypofractionated vs. conventional radiotherapy in high risk prostate cancer: systematic review and meta analysis.
Di Franco R; Borzillo V; Ravo V; Ametrano G; Cammarota F; Rossetti S; Romano FJ; D'Aniello C; Cavaliere C; Iovane G; Porricelli MA; Muto M; Berretta M; Facchini G; Muto P
Eur Rev Med Pharmacol Sci; 2017 Aug; 21(16):3563-3575. PubMed ID: 28925488
[TBL] [Abstract][Full Text] [Related]
18. Acute toxicity in prostate cancer patients treated with and without image-guided radiotherapy.
Gill S; Thomas J; Fox C; Kron T; Rolfo A; Leahy M; Chander S; Williams S; Tai KH; Duchesne GM; Foroudi F
Radiat Oncol; 2011 Oct; 6():145. PubMed ID: 22035354
[TBL] [Abstract][Full Text] [Related]
19. Hypofractionated versus conventionally fractionated radiotherapy for patients with localised prostate cancer (HYPRO): final efficacy results from a randomised, multicentre, open-label, phase 3 trial.
Incrocci L; Wortel RC; Alemayehu WG; Aluwini S; Schimmel E; Krol S; van der Toorn PP; Jager H; Heemsbergen W; Heijmen B; Pos F
Lancet Oncol; 2016 Aug; 17(8):1061-1069. PubMed ID: 27339116
[TBL] [Abstract][Full Text] [Related]
20. "Give me five" ultra-hypofractionated radiotherapy for localized prostate cancer: non-invasive ablative approach.
Marvaso G; Riva G; Ciardo D; Gandini S; Fodor C; Zerini D; Colangione SP; Timon G; Comi S; Cambria R; Cattani F; De Cobelli O; Orecchia R; Jereczek-Fossa BA
Med Oncol; 2018 May; 35(6):96. PubMed ID: 29748830
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]